🧬 Large-Scale Suspension AAV Viral Vector CDMO

Suspension Bioreactor AAV Gene Therapy Plant Model

Underwrite 2,000L single-use suspension bioreactor facilities manufacturing clinical-grade Adeno-Associated Virus (AAV9/AAV2) vectors for rare monogenic disease gene therapies. Model biotech batch reservations ($4.2M/batch), and 20-yr project IRR.

1. Capacity & Unit Economics

Annual AAV Production Batches (Batches / Yr)

Biotech CDMO Batch Contract ($M / Batch)

Triple Transfection Plasmids & Resins OpEx ($M / Batch)

Suspension Bioreactors & Analytics CapEx ($M)

2. Financial Returns & Yield

CLINICAL-GRADE AAV VECTORS

Annual Net EBITDA

$0 / yr

20-Yr Project IRR

0.0%

Gross Revenue

$0 / yr

Total CapEx

Annual OpEx

$0 / yr